Nordson (NDSN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
19 Feb, 2026Executive summary
Achieved record first quarter sales of $669.5 million, up 9% year-over-year, with 7% organic growth and broad-based segment contributions, especially from Advanced Technology Solutions (ATS) and strong Asia Pacific demand.
Net income rose to $133.4 million, or $2.38 per diluted share, a 44% increase year-over-year, benefiting from a non-cash gain on a minority technology investment.
Adjusted EPS reached $2.37, up 15% from the prior year, exceeding guidance midpoint.
EBITDA reached a record $203 million, representing 30% of sales, up 8% year-over-year, with strong cash flow performance.
Backlog increased approximately 4% year-over-year, supporting a positive outlook.
Financial highlights
Net sales: $669.5 million, up from $615.4 million year-over-year, with 7% organic growth and a 4% positive currency impact, partially offset by a small divestiture.
Adjusted operating profit grew 10% to $166.4 million; EBITDA margin held at 30% despite mix headwinds.
Net income was $133.4 million ($2.38 per share); adjusted EPS was $2.37, up 15% year-over-year.
Gross margin was 54.7%, nearly flat compared to 54.6% in the prior year.
Free cash flow was $123 million, with a conversion rate of 105% for the third consecutive quarter.
Outlook and guidance
Second quarter sales expected between $710 million and $740 million; adjusted EPS forecasted at $2.70–$2.90.
Full-year sales guidance raised to $2.86–$2.98 billion (up 4.5% at midpoint); adjusted EPS guidance increased to $11–$11.60 (up 10% at midpoint).
Backlog grew approximately 4% year-over-year, with strong order entry trends, especially in ATS.
Guidance assumes continued electronics momentum and modest improvement in industrial/automotive; lower end assumes potential demand pullback in H2.
Latest events from Nordson
- Strong growth, innovation, and cash flow support 6-8% annual revenue growth through 2029.NDSN
Investor presentation19 Feb 2026 - Q3 sales up 2% to $662M; Atrion acquisition expands medical segment; guidance raised.NDSN
Q3 202423 Jan 2026 - 2025–2029 targets 6%-8% revenue and 10%-12% EPS growth, driven by strategy and portfolio evolution.NDSN
Investor Day 202420 Jan 2026 - Shareholders will vote on directors, auditor ratification, and executive pay amid record results and strong governance.NDSN
Proxy Filing16 Jan 2026 - Annual meeting to elect directors, ratify auditor, and approve executive pay, all board-recommended.NDSN
Proxy Filing16 Jan 2026 - Record sales and EBITDA in 2024; 2025 outlook targets growth, led by Atrion amid macro uncertainty.NDSN
Q4 202411 Jan 2026 - Sales fell 2.8% but backlog surged 15%, signaling growth potential for 2025.NDSN
Q1 20258 Jan 2026 - Record sales, strong margins, and robust cash flow set up for solid growth in 2026.NDSN
Q4 202512 Dec 2025 - Record financials, strong governance, and key votes headline the 2025 proxy.NDSN
Proxy Filing1 Dec 2025